[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"liver-dysfunction\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:liver-dysfunction":25},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,8,0,[8,43,73,105,133,160,189,211],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":15,"eligibilityCriteria":16,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":19,"targetDuration":4,"studyType":22,"phases":4,"briefSummary":23,"conditions":24,"keywords":26,"overallStatus":30,"whyStopped":4,"lastUpdateSubmitDate":31,"lastUpdatePostDateStruct":32,"startDateStruct":35,"completionDateStruct":37,"leadSponsor":39,"locationsCount":42},"100300598","diagnostic-and-therapeutic-applications-of-microarrays-in-liver-transplantation-100300598",false,"NCT03193151","Diagnostic and Therapeutic Applications of Microarrays in Liver Transplantation","Diagnostic and Therapeutic Applications of Microarrays in Liver Transplantation, a Multicenter Study","INTERLIVER","Inclusion Criteria:\n\n* biopsy for clinical indications\n\nExclusion Criteria:\n\n* no consent, pregnant women","ALL","18 Years",{"count":20,"type":21},300,"ESTIMATED","OBSERVATIONAL","INTERLIVER is a prospective observational study of the relationship of the molecular phenotype of 300 liver transplant biopsies to the histologic phenotype and the clinical features and outcomes. A segment of a biopsy performed as standard-of-care for indications, or by center protocol, will be used for gene expression study.",[25],"Liver Dysfunction",[27,28,29],"Liver transplant","global gene expression","molecular diagnostics","RECRUITING","2026-06-01",{"date":33,"type":34},"2026-06-04","ACTUAL",{"date":36,"type":34},"2017-12-19",{"date":38,"type":21},"2028-12",{"name":40,"class":41},"University of Alberta","OTHER",15,{"id":44,"slug":45,"hasResults":11,"nctId":46,"briefTitle":47,"officialTitle":48,"acronym":49,"eligibilityCriteria":50,"healthyVolunteers":11,"sex":17,"minAge":4,"maxAge":51,"enrollmentInfo":52,"targetDuration":4,"studyType":54,"phases":55,"briefSummary":57,"conditions":58,"keywords":60,"overallStatus":62,"whyStopped":4,"lastUpdateSubmitDate":63,"lastUpdatePostDateStruct":64,"startDateStruct":66,"completionDateStruct":68,"leadSponsor":70,"locationsCount":72},"100604052","prevalence-of-liver-dysfunction-in-pediatric-patients-with-congenital-heart-disease-at-assiut-100604052","NCT07144501","Prevalence of Liver Dysfunction in Pediatric Patients With Congenital Heart Disease at Assiut.","Prevalence of Liver Dysfunction in Paediatric Patients With Congenital Heart Disease: A Cross-Sectional Study at Assiut University Children Hospital.","CHD","Inclusion Criteria:\n\n* Confirmed pediatric CHD patients attending Assiut University Children's Hospital.\n* Age: from birth up to 16 years old.\n\nExclusion Criteria:\n\n* Patients with primary liver disease.\n* Recent cardiac surgery (\\\u003C3 m) (to exclude acute postoperative liver injury).\n* Active systemic infection\u002Fsepsis (to avoid confounding liver enzyme elevations).","16 Years",{"count":53,"type":21},40,"INTERVENTIONAL",[56],"NA","Liver dysfunction is a well-documented complication in patients with congenital heart disease (CHD). The mechanisms leading to hepatic dysfunction may be multifactorial. Key risk factors for liver dysfunction in CHD include prolonged hypoxemia, high venous pressure, and prolonged duration of heart disease.\n\nWhile global studies have extensively explored this association, the prevalence of liver dysfunction in CHD varies, with studies reporting hepatic fibrosis in 30-40% of Fontan patients, while regional data, particularly from Egypt, remain limited.\n\nIn this research we aim to determine the prevalence of biochemical and radiological hepatic abnormalities in pediatric CHD patients attending Assiut University Children's Hospital.",[59,25],"Congenital Heart Disease",[49,61],"Liver dysfunction","NOT_YET_RECRUITING","2025-08-25",{"date":65,"type":34},"2025-08-27",{"date":67,"type":21},"2025-09-15",{"date":69,"type":21},"2026-03-15",{"name":71,"class":41},"Assiut University",1,{"id":74,"slug":75,"hasResults":11,"nctId":76,"briefTitle":77,"officialTitle":78,"acronym":79,"eligibilityCriteria":80,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":81,"targetDuration":4,"studyType":54,"phases":83,"briefSummary":85,"conditions":86,"keywords":89,"overallStatus":62,"whyStopped":4,"lastUpdateSubmitDate":95,"lastUpdatePostDateStruct":96,"startDateStruct":98,"completionDateStruct":100,"leadSponsor":102,"locationsCount":104},"100589129","phase-2-normothermic-oxygenated-perfusion-nmp-viability-testing-before-transplantation-of-discarded-livers-100589129","NCT06950398","Normothermic Oxygenated Perfusion (NMP) Viability Testing Before Transplantation of Discarded Livers","Normothermic Oxygenated Perfusion (NMP) Viability Testing Before Transplantation of Discarded Livers. An Open Label, Non-randomized, Prospective, Single Arm Trial","TRANSPERF","INCLUSION CRITERIA :\n\nFOR LIVER DONORS\n\n* Donation after brainstem death (DBD)\n* Liver graft refused by 5 different transplant centres and after rescue allocation (\"hors tour\")\n\nFOR LIVER TRANSPLANT RECIPIENTS\n\n* ≥ 18 years old\n* Candidates for a first elective liver transplantation (patients with a pre-transplant work-up excluding: re-transplantation, emergency transplantation (e.g. fulminant hepatitis), multi-organ or heterotopic transplantation)\n* UNOS status IV (non-ventilated, no vasopressor support)\n* Absence of renal insufficiency defined as a GFR of less than 60 mL\u002Fmin\u002F1.73 m² for three months or more\n* MELD Score ≤ 25\n* Willing and able to attend follow-up examinations\n* Having signed an informed consent document\n\nNON-INCLUSION CRITERIA:\n\nFOR LIVER DONORS\n\n* Macroscopic features of advanced fibrosis or cirrhosis at procurement\n* Transplantation using a split graft, in situ or ex situ\n* Estimated cold ischemic time greater than 8 hours (5 hours maximum of graft transport in cold ischemia)\n\nFOR LIVER TRANSPLANT RECIPIENTS\n\n* Mentally or legally incapacitated\n* Transplantation for fulminant hepatic failure\n* Early or late re-transplantation\n* Combined liver transplant with any other organ, en-bloc or not\n* Heterotopic liver transplantation",{"count":82,"type":21},99,[84],"PHASE2","Liver transplantation (LT) is a highly effective treatment for end-stage liver disease and early-stage primary liver cancer. As such, the demand for donor livers greatly exceeds supply; in 2021 in France, 12.9% of patients on the waitlist either died or were delisted for worsening of their condition.\n\nHowever a substantial number of perfectly viable organs are wrongly discarded based on a highly subjective assessment as the level of acceptance varies widely depending on the physician's judgement.\n\nThe idea of using Normothermic Machine Perfusion (NMP) not only to preserve the liver graft but also for selection purposes is a concept that has been already investigated. A few trials have analyzed the value of normothermic perfusion to assess rejected liver grafts.\n\nSeveral teams demonstrated that NMP provides a tool to assess organ viability pre-transplantation as the liver is able to maintain an almost physiological metabolism.\n\nThese preliminary results came from small samples, 45% of which originated from donation after circulatory death (DCD). They need confirmation in a larger sample of organs from donors with brainstem death (DBD), adapted to the French liver allocation system.\n\nThis trial will reproduce and confirm the results of the previous studies in order to establish viability testing as the de facto method for high-risk or rejected grafts. It will also validate existing viability markers so as to define a new standard for viability testing using NMP.",[87,25,88],"Organ Transplantation","Liver Diseases",[90,91,92,93,94],"Liver Transplantation","Normothermic oxygenated perfusion","NMP","Discarded livers","Viability assessment","2025-08-14",{"date":97,"type":34},"2025-08-15",{"date":99,"type":21},"2025-12-15",{"date":101,"type":21},"2029-06-15",{"name":103,"class":41},"Rennes University Hospital",6,{"id":106,"slug":107,"hasResults":11,"nctId":108,"briefTitle":109,"officialTitle":110,"acronym":4,"eligibilityCriteria":111,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":112,"enrollmentInfo":113,"targetDuration":4,"studyType":22,"phases":4,"briefSummary":115,"conditions":116,"keywords":120,"overallStatus":30,"whyStopped":4,"lastUpdateSubmitDate":124,"lastUpdatePostDateStruct":125,"startDateStruct":127,"completionDateStruct":129,"leadSponsor":131,"locationsCount":72},"100529451","ssm-predicts-outcomes-of-cld-inpatients-with-acute-liver-injury-100529451","NCT06173947","SSM Predicts Outcomes of CLD Inpatients With Acute Liver Injury","Spleen Stiffness Measurement Predicts Short-term Outcomes of Chronic Liver Disease Inpatients With Acute Liver Injury: a Prospective, Observational and Multicentre Study","Inclusion Criteria:\n\n1. Age between 18 years and 80 years\n2. Chronic liver diseases regardless of etiology\n3. Acute liver injury with total bilirubin ≥ 3 mg\u002Fdl regardless of inducement\n\nExclusion Criteria:\n\n1. Prior surgery of liver diseases before enrollment such as liver transplantation, transjugular intrahepatic portosystemic shunt (TIPS), splenectomy and partial splenic embolization\n2. Severe extrahepatic diseases such as chronic obstructive pulmonary disease level IV, chronic kidney disease with end-stage renal failure, myocardial infarction within 3 months before admission\n3. Receiving Immunosuppressive drugs for reasons rather than chronic liver diseases\n4. Diagnosis of hepatocellular carcinoma or other non-liver malignancies during screening period\n5. Serious mental illnesses such as anxiety, depressive disorders to obsessive-compulsive disorder (OCD) and post-traumatic stress disorder (PTSD)\n6. The pregnant\n7. Jaundice due to biliary obstruction or cholestasis\n8. Unsuitable to participate in this study judging by investigators","80 Years",{"count":114,"type":21},411,"In this study, a single non-invasive tool, spleen stiffness measurement (SSM), was used to monitor the disease regression of inpatients with chronic liver disease (CLD) and acute liver injury. The present study aimed to establish an early diagnosis warning model for acute-on-chronic liver failure (ACLF) by SSM and investigate the effect of dynamic changes in SSM on the short-term prognosis (28-day, 90-day morbidity and mortality) of inpatients with CLD and acute liver injury.",[117,118,25,119],"End Stage Liver Disease","Jaundice","Portal Hypertension",[117,121,122,123,119,118],"Chronic Liver Disease","Spleen Stiffness Measurement","Acute-on-Chronic Liver Failure","2025-05-19",{"date":126,"type":34},"2025-05-21",{"date":128,"type":34},"2024-01-01",{"date":130,"type":21},"2025-12-30",{"name":132,"class":41},"Nanfang Hospital, Southern Medical University",{"id":134,"slug":135,"hasResults":11,"nctId":136,"briefTitle":137,"officialTitle":138,"acronym":139,"eligibilityCriteria":140,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":141,"targetDuration":143,"studyType":22,"phases":4,"briefSummary":144,"conditions":145,"keywords":4,"overallStatus":62,"whyStopped":4,"lastUpdateSubmitDate":151,"lastUpdatePostDateStruct":152,"startDateStruct":154,"completionDateStruct":156,"leadSponsor":158,"locationsCount":4},"100529786","descripitive-patient-analysis-to-enable-risk-based-quality-improvement-measures-in-a-large-internal-medicine-group-practice-100529786","NCT06178302","DEscripitive Patient Analysis to Enable Risk-based Quality Improvement Measures in a lArge iNternal mediCIne grouP Practice","DEscripitive Patient Analysis to Enable Risk-based Quality Improvement Measures in a lArge iNternal mediCIne grouP Practice - The EMANCIPATE Study","EMANCIPATE","1. Female or male patients aged above 18 years diagnosed with chronic liver disease, undergo on-site endoscopy, suffer from atherosclerosis, heart failure, are diagnosed with abnormal serum thyroid-stimulating hormone (TSH) levels, either overt or latent hypo- or hyperthyroidism, or are diagnosed with solitary or multiple thyroid nodules.\n2. Routine laboratory results available within the last 3 months.\n3. Available imaging data within the last 3 months performed on site.",{"count":142,"type":21},1000,"10 Years","Background: Clinical trials often include patients from large hospitals or university clinics. Information on patients cared for at offices from statutory health insurance-accredited physicians represent evidence gaps.\n\nAims\u002FObjectives:\n\nThe present study has three aims: First, to systematically describe the patient population of a large group practice for internal medicine. Second, to identify high-risk patients using established risk scores. And third, to include routine imaging data to optimize patient management.\n\nMethods\u002FFacility Enrolling Participants: This is a prospective, observational study assessing patients' baseline characteristics, risk evaluation and integrating data from imaging test. The setting of the present study is a large group practice for internal medicine which consists of statutory health insurance-accredited physicians. Study participants will be included during daily routine, real-world clinical care and therefore represent all-comers fulfilling the inclusion criteria:\n\n1. Female or male patients aged above 18 years diagnosed with chronic liver disease, undergo on-site endoscopy, suffer from atherosclerosis, heart failure, are diagnosed with abnormal serum thyroid-stimulating hormone (TSH) levels, either overt or latent hypo- or hyperthyroidism, or are diagnosed with solitary or multiple thyroid nodules.\n2. Routine laboratory results available within the last 3 months.\n3. Available imaging data within the last 3 months performed on site. Perspective: The study is designed to evaluate the current situation and quality of health care in defined patient populations in the routine clinical setting of a large-scale public office. These data will provide a profound rationale to identify quality issues and limitations in our performance of guideline-conform treatment in routine patient care.",[25,146,147,148,149,150],"Thyroid","Atherosclerosis","Heart Failure","Intestinal Disease","Heart Diseases","2025-05-05",{"date":153,"type":34},"2025-05-07",{"date":155,"type":21},"2025-12",{"date":157,"type":21},"2035-06",{"name":159,"class":41},"Imed19",{"id":161,"slug":162,"hasResults":11,"nctId":163,"briefTitle":164,"officialTitle":165,"acronym":4,"eligibilityCriteria":166,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":167,"targetDuration":4,"studyType":54,"phases":169,"briefSummary":170,"conditions":171,"keywords":174,"overallStatus":30,"whyStopped":4,"lastUpdateSubmitDate":180,"lastUpdatePostDateStruct":181,"startDateStruct":183,"completionDateStruct":185,"leadSponsor":187,"locationsCount":72},"100525798","application-of-high-dose-insulin-therapy-to-improve-liver-function-and-regeneration-100525798","NCT06126419","Application of High-dose Insulin Therapy to Improve Liver Function and Regeneration","Application of High-Dose Insulin Therapy Using a Hyperinsulinemic Normoglycemic Clamp to Improve Liver Function and Regeneration","Inclusion Criteria:\n\n* Age \\> 18 years old\n* Candidate for major liver resection\n* Resectable colorectal liver metastasis\n\nExclusion Criteria:\n\n* Inability to give consent\n* Type 1 diabetes mellitus\n* Uncontrolled blood glucose levels (fasting level \\> 10 mmol\u002FL)\n* Unresectable colorectal liver metastasis\n* Extrahepatic metastatic disease that is unresectable",{"count":168,"type":21},70,[56],"The primary objective of this interventional study is determine if the future liver remnant can be optimized by improving liver function pre-operatively in patients who are scheduled for major hepatectomy. The main questions it aims to answer are:\n\n1. Does high-dose insulin therapy improve liver function in the pre-operative setting?\n2. What is the effect of high-dose insulin therapy on liver function and liver regeneration after a liver venous deprivation (LVD) procedure?\n3. What is the relationship between volume hypertrophy and function in the regenerating liver? Participants will receive a 6-hour infusion of insulin and dextrose to maintain a hyperinsulinemic-normoglycemic state in the weeks prior to planned liver surgery to assess its effect on liver function measured by 99m-Tc-Mebrofenin hepatobiliary scintigraphy.",[25,172,173],"Liver Metastasis Colon Cancer","Liver Regeneration",[175,176,177,178,179],"Hyperinsulinemic-Normoglycemic Clamp","High Dose Insulin Therapy","99mTc-Mebrofenin Hepatobiliary Scintigraphy","Colorectal Cancer Liver Metastasis","Liver Resection","2024-11-18",{"date":182,"type":34},"2024-11-20",{"date":184,"type":34},"2023-11-08",{"date":186,"type":21},"2026-12",{"name":188,"class":41},"McGill University Health Centre\u002FResearch Institute of the McGill University Health Centre",{"id":190,"slug":191,"hasResults":11,"nctId":192,"briefTitle":193,"officialTitle":193,"acronym":4,"eligibilityCriteria":194,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":112,"enrollmentInfo":195,"targetDuration":4,"studyType":22,"phases":4,"briefSummary":197,"conditions":198,"keywords":200,"overallStatus":30,"whyStopped":4,"lastUpdateSubmitDate":204,"lastUpdatePostDateStruct":205,"startDateStruct":207,"completionDateStruct":208,"leadSponsor":210,"locationsCount":72},"100556984","clinical-retrospective-study-analysis-of-postoperative-complications-following-hepatectomy-100556984","NCT06532214","Clinical Retrospective Study Analysis of Postoperative Complications Following Hepatectomy","Inclusion Criteria:\n\n* 1\\. Patients aged 18-80 years 2.Patients who underwent liver resection surgery at the participating centers\n\nExclusion Criteria:\n\n* Exclusion criteria are as follows:\n\n  1. Prior cancer treatments such as transarterial chemoembolization, ablation, or targeted therapy.\n  2. Repeat liver resection surgeries.\n  3. Presence of other malignancies.\n  4. Concurrent end-stage diseases including active infections, respiratory failure, decompensated heart failure, and autoimmune disease exacerbations.\n  5. Inadequate clinical data availability in medical records.",{"count":196,"type":21},2000,"Hepatectomy is a crucial surgical method for treating liver diseases such as liver cancer, hepatic hemangiomas, and biliary stones. Although hepatectomy has achieved significant therapeutic effects, postoperative complications remain an inevitable issue. Complications following hepatectomy include liver failure, hepatic vascular thrombosis, wound infection at the hepatic incision, and bile leakage, among others. These complications pose a serious threat to patients' health and life, and also increase the waste of medical resources and the cost of treatment. Currently, research on postoperative complications of hepatectomy mainly focuses on small sample studies from a single center, and most studies only focus on a specific complication, lacking comprehensive and systematic analysis. Therefore, it is necessary to conduct a retrospective study analysis of complications related to hepatectomy to more comprehensively and objectively understand the incidence, risk factors, prevention, and treatment of postoperative complications, providing clinical doctors with more scientific treatment plans and guidance.",[199,25],"Liver Failure",[201,202,203],"hepatectomy","liver failure","Post-hepatectomy liver failure","2024-07-29",{"date":206,"type":34},"2024-08-01",{"date":128,"type":34},{"date":209,"type":21},"2025-12-31",{"name":132,"class":41},{"id":212,"slug":213,"hasResults":11,"nctId":214,"briefTitle":215,"officialTitle":215,"acronym":216,"eligibilityCriteria":217,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":218,"enrollmentInfo":219,"targetDuration":4,"studyType":22,"phases":4,"briefSummary":221,"conditions":222,"keywords":4,"overallStatus":30,"whyStopped":4,"lastUpdateSubmitDate":225,"lastUpdatePostDateStruct":226,"startDateStruct":228,"completionDateStruct":230,"leadSponsor":232,"locationsCount":72},"100500203","single-center-prospective-study-of-non-invasive-methods-for-the-diagnosis-of-postoperative-complications-in-liver-transplant-recipients-100500203","NCT05793203","Single-center Prospective Study of Non-invasive Methods for the Diagnosis of Postoperative Complications in Liver Transplant Recipients","ElastOLT","Inclusion Criteria:\n\n* Patients eligible for liver transplantation following National and International Guidelines\n\nExclusion Criteria:\n\n* No agreement or inability to give informed consent\n\n  * Re-transplant patients\n  * Liver transplant in fulminant hepatitis","75 Years",{"count":220,"type":21},100,"A lot of different early and late complications may occur after liver transplantation. They could be related to surgical procedure, to infectious diseases or immuno-mediated diseases (acute cellular rejection, ACR). Almost all of those complications are characterized by an elevation in liver enzymes (ALT, AST and GGT) and a decline of liver function tests (serum bilirubin and INR increase) possibly leading to early allograft disfunction (EAD). In this scenario there is a lack of biomarker that could predict the development of ACR and\u002For EAD.\n\nThe aim of this study is to explore the prognostic role of non-invasive instrumental and biological marker in the early post-transplant phase.",[223,224,25],"Rejection Acute Hepatic","Transplant; Failure, Liver","2023-03-20",{"date":227,"type":34},"2023-03-31",{"date":229,"type":34},"2020-07-06",{"date":231,"type":21},"2027-12-31",{"name":233,"class":41},"Fondazione Policlinico Universitario Agostino Gemelli IRCCS"]